Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. (Q40960198)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 December 2015

Language	Label	Description	Also known as
English	Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.	scientific article published on 21 December 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Jesus Berdeja

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

Sundar Jagannath

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

Jeffrey Zonder

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

Ashraf Badros

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

Jonathan L Kaufman

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

Robert Manges

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

Manish Gupta

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

Amol Tendolkar

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

Mark Lynch

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

Eric Bleickardt

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

Prashni Paliwal

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

Ravi Vij

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

language of work or name

0 references

publication date

21 December 2015

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Clinical Lymphoma, Myeloma & Leukemia

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

129-138

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal Failure in Multiple Myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current approach to diagnosis and management of acute renal failure in myeloma patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterizing the impact of renal impairment on the clinical pharmacology of biologics

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International uniform response criteria for multiple myeloma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal failure in multiple myeloma: incidence, correlations, and prognostic significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26795075

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.CLML.2015.12.007

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6857171&resulttype=core&format=json

13 May 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40960198&oldid=2143977269"